INV-202 Induces Weight Loss and Reduces Airway Hyperreactivity in Mouse Model of Obese AsthmaMONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address co
Research highlights the potential of Enveric’s EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but reduce pharmacological exposureCAMBRIDGE, Mass.--(BUSINESS
EB Research Partnership (“EBRP”) invested in Krystal Biotech by way of a private placement after Krystal’s Biotech’s initial public offering in 2017 using EBRP’s Venture Philanthropy model. This is not only the first-ever FDA approved treatme
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addic
Anniversary campaign features a unique microsite and call for stories.WASHINGTON--(BUSINESS WIRE)--#BoldResearchCan--In celebration of its 50th anniversary, BrightFocus Foundation announces the launch of a yearlong campaign and microsite celebrating the
The positive vote is based on compelling scientific evidence presented, including Phase 3 efficacy and safety data in pregnant individuals and their infants FDA decision expected in August 2023 If authorized, the vaccine candidate would help protect
MIEBO is the First and Only Prescription Eye Drop Approved for Dry Eye Disease that Directly Targets Tear Evaporation, Based on Consistent Results from Two Consecutive Pivotal Phase 3 TrialsVAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)--Bausch
Fluence LEDs selected to enable Acceleration Platform for Innovation, a program helping companies participate in research advancing medical cannabis production across EMEAAUSTIN, Texas & ROTTERDAM, Netherlands--(BUSINESS WIRE)--Fluence, a leading global
Intellectual property describes composition of matter claims governing Enveric’s lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorderCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB)
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances fe
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.